Globe Biotech has won the first United States pharmaceutical patent ever granted to a Bangladeshi company for its homegrown single-dose mRNA Covid-19 vaccine, Bangavax, a milestone that experts say could expand local research and give the country a stronger role in global health. The patent grants Globe Biotech exclusive rights to the vaccine technology for twenty years, and company scientists say the same platform can be adapted to develop mRNA vaccines for diseases such as dengue and Nipah and to support production of other biologic medicines. At a press briefing, Globe researchers said Bangavax is the only single-dose mRNA vaccine developed in the country and that the US patent will help them share the technology with partners, sell products abroad, and keep control of the innovation at home. Industry groups and academics praised the achievement as proof that Bangladeshi firms can do high-level research when they invest in long-term science and stay the course through hard steps. Observers noted the team faced delays in trials and approvals but kept working until the invention earned international recognition, and that persistence is now seen as a model for other companies. Experts also highlighted practical benefits: the patented platform can cut the cost of making advanced vaccines locally, help adapt shots quickly to new threats, and support work on complex biologic medicines that used to be made overseas. Local trade and industry representatives said the patent boosts brand value and may attract partners, training, and funding that will help build labs and factories. Scientists called for clear rules on licensing, stronger testing and quality control labs, and training programs so the country can use the patent to grow skilled jobs in life sciences. Globe Biotech leaders urged industry and policy makers to back testing, clinical work and fair licensing so the innovation leads to real products that reach patients at low cost. The move may also encourage more ties between companies and universities so students learn hands-on skills and researchers solve real problems for medicine and public health. For communities that supply parts of the supply chain, such as small firms that pack, transport or test medicines, a stronger pharma sector could bring new work and steadier incomes. Overall, the patent is a sign that local science can win global respect, and that with careful follow-up on training, quality control and business support, one homegrown invention can grow into wider health benefits, export chances and new jobs for many people.
